Literature DB >> 20395516

Comprehensive and efficient HBB mutation analysis for detection of beta-hemoglobinopathies in a pan-ethnic population.

Owen T M Chan1, Kenneth D Westover, Lisa Dietz, James L Zehnder, Iris Schrijver.   

Abstract

Current methods that assay hemoglobin beta-globin chain variants can have limited clinical sensitivity when applied techniques identify only a predefined panel of mutations. Even sequence-based assays may be limited depending on which gene regions are investigated. We sought to develop a clinically practical yet inclusive molecular assay to identify beta-globin mutations in multicultural populations. We highlight the beta-globin mutation detection assay (beta-GMDA), an extensive gene sequencing assay. The polymerase chain reaction (PCR) primers are located to encompass virtually all hemoglobin beta locus (HBB) mutations. In addition, this assay is able to detect, by gap PCR, a common large deletion (Delta619 base pair), which would be missed by sequencing alone. We describe our 5-year experience with the beta-GMDA and indicate its capability for detecting homozygous, heterozygous, and compound heterozygous sequence changes, including previously unknown HBB variants. The beta-GMDA offers superior sensitivity and ease of use with comprehensive detection of HBB mutations that result in beta-globin chain variants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20395516     DOI: 10.1309/AJCP7HQ2KWGHECIO

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Characterization of Deletions of the HBA and HBB Loci by Array Comparative Genomic Hybridization.

Authors:  Daniel E Sabath; Michael A Bender; Vijay G Sankaran; Esther Vamos; Alex Kentsis; Hye-Son Yi; Harvey A Greisman
Journal:  J Mol Diagn       Date:  2015-11-21       Impact factor: 5.568

2.  Fatal 1918 pneumonia case complicated by erythrocyte sickling.

Authors:  Zong-Mei Sheng; Daniel S Chertow; David M Morens; Jeffery K Taubenberger
Journal:  Emerg Infect Dis       Date:  2010-12       Impact factor: 6.883

3.  Genotype-phenotype association analysis identifies the role of α globin genes in modulating disease severity of β thalassaemia intermedia in Sri Lanka.

Authors:  Shiromi Perera; Angela Allen; Ishari Silva; Menaka Hapugoda; M Nirmali Wickramarathne; Indira Wijesiriwardena; Stephen Allen; David Rees; Dimitar G Efremov; Christopher A Fisher; David J Weatherall; Anuja Premawardhena
Journal:  Sci Rep       Date:  2019-07-12       Impact factor: 4.379

4.  Next-generation sequencing improves molecular epidemiological characterization of thalassemia in Chenzhou Region, P.R. China.

Authors:  Haoqing Zhang; Caiyun Li; Jianbiao Li; Shuai Hou; Danjing Chen; Haiying Yan; Shiping Chen; Saijun Liu; Zhenzhen Yin; Xiaoqin Yang; Jufang Tan; Xiaoyan Huang; Liming Zhang; Junbin Fang; Caifen Zhang; Wei Li; Jian Guo; Dongzhu Lei
Journal:  J Clin Lab Anal       Date:  2019-02-27       Impact factor: 2.352

5.  Efficient detection of Mediterranean β-thalassemia mutations by multiplex single-nucleotide primer extension.

Authors:  Biljana Atanasovska; Georgi Bozhinovski; Dijana Plaseska-Karanfilska; Lyubomira Chakalova
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

6.  Frequencies of Beta Thalassemia Mutations Show Different Pattern in Bannu Region than Other Parts of Pashtun Population in Khyber Pakhtunkhwa Province Pakistan.

Authors:  Shoaib U Rehman; Muhammad Shakeel; Maimoona Azam; Sadaf Akhtar; Rauf Niazi
Journal:  Indian J Hematol Blood Transfus       Date:  2021-02-26       Impact factor: 0.915

7.  Use of an automated pyrosequencing technique for confirmation of sickle cell disease.

Authors:  Camila Cruz de Martino; Cecilia Salete Alencar; Paula Loureiro; Anna Barbara de Freitas Carneiro-Proietti; Claudia de Alvarenga Máximo; Rosimere Afonso Mota; Daniela Oliveira Werneck Rodrigues; Nelson Gaburo Junior; Shannon Kelly; Ester Cerdeira Sabino
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.